ProQR Therapeutics (NASDAQ:PRQR – Free Report) was the target of a large drop in short interest in June. As of June 15th, there was short interest totalling 525,200 shares, a drop of 34.0% from the May 31st total of 796,200 shares. Based on an average daily volume of 690,100 shares, the days-to-cover ratio is currently […]
ProQR Therapeutics (NASDAQ:PRQR – Get Rating) was upgraded by analysts at StockNews.com from a “hold” rating to a “buy” rating in a research report issued on Thursday. Several other analysts also recently weighed in on the company. Cantor Fitzgerald dropped their price target on ProQR Therapeutics from $5.00 to $4.50 in a research note on […]
Opaleye Management Inc. trimmed its stake in shares of ProQR Therapeutics (NASDAQ:PRQR – Get Rating) by 53.1% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 1,460,000 shares of the biopharmaceutical company’s stock after selling 1,655,000 shares during the period. ProQR Therapeutics makes up […]
StockNews.com upgraded shares of ProQR Therapeutics (NASDAQ:PRQR – Get Rating) from a sell rating to a hold rating in a research report sent to investors on Saturday morning. Several other research firms also recently issued reports on PRQR. JMP Securities raised shares of ProQR Therapeutics from a market perform rating to an outperform rating and […]
StockNews.com upgraded shares of ProQR Therapeutics (NASDAQ:PRQR – Get Rating) from a sell rating to a hold rating in a research note published on Saturday. Several other brokerages also recently weighed in on PRQR. Citigroup decreased their target price on shares of ProQR Therapeutics from $3.00 to $2.25 in a research note on Friday, April […]